Patent · US Active

Crystalline ethyl 4-[4-[(2R)-3-[4-amino-3-chloro-5-(trifluoromethyl)phenyl]-1-oxo-2-[[[4-(1,2,4,5-tetrahydro-2-oxo-3H-1,3-benzodiazepin-3-yl)-1-piperidinyl]carbonyl]oxy]propyl]-1-piperazinyl]-piperidine-1-acetate difumarate

US8551987B2 · kind B2 · utility

0Cited by

0References

2Claims

0Family size

Assignee

Boehringer Ingelheim International GmbH · DE

Inventors

Kathrin Pachur · Schwendi, DE
Uwe Ries · Biberach an der Riß, DE
Ulrike Werthmann · Biberach an der Riß, DE
Sonja Sproll · Ochsenhausen, DE

Key dates

Filing date	Sep 25, 2008
Grant date	Oct 8, 2013
Priority date	—
Expiry date	Apr 26, 2029

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the novel salts AB of the base A with a physiologically acceptable acid B which is selected from the group consisting of hydrochloric acid, hydrobromic acid, sulfuric acid, fumaric acid and salicylic acid and the polymorphic compounds, the corresponding solvates and hydrates thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.